Physician profile
Wesley D Granger
NPI 1023030426
$2,478.41
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $792 · 2021: $717 · 2022: $182 · 2023: $42.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.67 | 2019-2022 | |
| Amgen INC. | $318.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $290.14 | 2019-2021 | |
| Abbvie INC. | $208.46 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $177.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.57 | 2019-2022 | |
| Amarin Pharma, INC. | $146.41 | 2019-2022 | |
| Pfizer INC. | $108.70 | 2019-2022 | |
| Allergan, INC. | $106.62 | 2019-2020 | |
| Esperion Therapeutics, INC. | $79.25 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.45 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.13 | 2019-2022 | |
| Lilly USA, LLC | $47.93 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.97 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $32.11 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $25.95 | 2021 | |
| Ironwood Pharmaceuticals, INC | $24.65 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $23.50 | 2019 | |
| Corcept Therapeutics | $19.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.23 | 2021 | |
| Hikma Pharmaceuticals USA | $16.79 | 2022 | |
| Dexcom, INC. | $15.40 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.24 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $14.46 | 2019 | |
| Daiichi Sankyo INC. | $12.98 | 2020 | |
| Mission Pharmacal Company | $12.76 | 2019 | |
| Medicure Pharma INC. | $12.18 | 2021 | |
| Merck Sharp & Dohme LLC | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Granger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.